PBS should pay for Abiraterone for all incurable prostate cancer patients
  • Petitioning The Hon Peter Dutton MP, Minister for Health, Parliament House, Canberra

This petition will be delivered to:

The Hon Peter Dutton MP, Minister for Health, Parliament House, Canberra

PBS should pay for Abiraterone for all incurable prostate cancer patients

    1. Tony Musgrave
    2. Petition by

      Tony Musgrave

      Australia

Many Australian men die from prostate cancer every year, most from advanced stages in the hormone resistant form

Abiraterone acetate (Zytiga) is a new proven medication that can prolong life and reduce pain in advanced prostate cancer sufferers. It has been shown to delay progression of the incurable hormone-refractory form of the cancer for months, and even years. The trouble is the drug costs around $3,500 per month.

The Pharmaceutical Benefits Scheme (PBS) does not cover the cost of Zytiga for these patients unless they first endure chemotherapy and its unpleasant side-effects. Only when this remedy fails might they qualify. As a result they are condemned to more pain and an earlier death than they should be, all because of cost-cutting by government authorities. This is discrimination based on type of disease and is very unfair.

The bottom line is this drug is given earlier it will increase survival time, reduce suffering and delay the need for chemotherapy. Therefore these excluded patients should also be able to receive it free on the PBS.

Please show your support for these Australian men by signing the email below and “click” to forward it to the federal health minister.

For references and a detailed discussion of the subject, "Incurable prostate cancer patients denied new medication on the PBS" please CLICK  here  or paste the following URL into the address pane of your web browser:

http://prostate-cancer-medication.blogspot.com.au/2012/08/chemotherapy-naive-patients-also.html

PS.: 31 Dec, 2013: The Hon Peter Dutton MP is now the Minister for Health There have already been 5,689 letters supporting this petition sent to his predecessor, The Hon Tanya Plibersek MP. During this time Abiraterone has been approved for PBS subsidy those patients whose chemotherapy with Docetaxel has failed but not for those who will also succumb but could have a pain-free extension of life without enduring chemotherapy first. The FDA has approved this but not the Therapeutics Goods Administration (TGA). This petition is therefore ongoing in the hope that these men will get a fair go from him. Every new signature that supporters can get will help.

 

 

 

Recent signatures

    News

    1. 05May14 - Abiraterone Petition presented to Minister Some action by PBAC

      Tony Musgrave
      Petition Organizer

      On 01May14 our Petition + a list of 5946 signatures and all the comments was delivered to the Health Minister. I urge new supporters to continue adding their signatures to the petition here at http://chn.ge/QsuSHc .

      In July The PBAC will consider extending PBS to mCRPC patients who have progressed following hormone treatment if they would not benefit from immediate chemotherapy (less than 10%?). How these are defined? Most patients will still not be eligible. It is good if those who can't tolerate chemo are included but it still is grossly inadequate. For 90% it's still to be toxic chemo even though abiraterone is kinder and effective but they can't afford the $3,500 pm, They won't be offered a PBS subsidy. Other than chemo their remaining option is an earlier, more painful death with palliative care to ease their passing.

      I urge you to make a PUBLIC SUBMISSION to the PBAC go> http://goo.gl/z4gZpQ deadline 11June-suggested text in my FB http://www.facebook.com/tony.pcm.5

      PBS should pay for Abiraterone for all incurable prostate cancer patients

      Many Australian men die from prostate cancer every year, most from advanced stages in the hormone resistant form Abiraterone acetate (Zytiga) is a...

    2. 8Apr14 2nd POST This is unfair because there is no PBS subsidy for them

      Tony Musgrave
      Petition Organizer

      Here is the rub. An incurable castrate resistant prostate cancer (mCRPC) patient whose hormone treatment (ADT) has failed can now purchase abiraterone if he is rich enough. Then there is a good chance he will live longer, free of pain. The majority can't afford this and so they only get the chemotherapy option with all its downside. This discriminatory. It is unfair because a PBS subsidy would level the playing field and give all the same chance. Cost to the Government might be another $30 million or so. There would be obvious offset savings because abiraterone is given as tablets at home with no need for expensive chemotherapy and in-patient resources.

      Two groups remain who still need a PBS subsidy,
      - those with metastatic CRPC and
      - those with pre-metastatic CRPC

      New supporters please sign petition (currently 5887 signatures) to Minister for Health Hon. Peter Dutton MP for abiraterone subsidy http://chn.ge/QsuSHc and perhaps email him direct at peter.dutton.mp@aph.gov.au

      PBS should pay for Abiraterone for all incurable prostate cancer patients

      Many Australian men die from prostate cancer every year, most from advanced stages in the hormone resistant form Abiraterone acetate (Zytiga) is a...

    3. Prostate cancer-TGA approves ABIRATERONE for some (at HUGE COST TO PT)

      Tony Musgrave
      Petition Organizer

      8Apr14 1st POST: Abiraterone now approved by TGA after failure of ADT therapy in metastatic castrate resistant prostate cancer (mCRPC) patients before chemotherapy-MUST PAY ½ of $3,500pm - rebate (See TGA http://goo.gl/bRSf4b)
      .
      Now there is discrimination between patients on the basis of income. As Abiraterone still has not been recommended for a PBS subsidy in this group this is unfair

      The TGA based its approval on, efficacy, safety profile, proven benefits eg decreased risk of disease progression, delay in the need for chemotherapy and opiate analgesia, oral treatment as an outpatient without the side effects and risks of chemotherapy, maintenance of quality of life, positive benefit-risk balance, approval by EU USA Canada New Zealand
      New supporters are invited to sign my petition (currently 5887signatures) to have abiraterone subsidized for the pre-chemotherapy group of advanced prostate cancer sufferers-See http://chn.ge/QsuSHc see also 8Apr 2nd POST

    4. Reached 5,000 signatures
    5. 17 May 2013 The FEDERAL BUDGET – Will the Minister approve Abiraterone?

      Tony Musgrave
      Petition Organizer

      Approval is urgently needed to list Abiraterone on the PBS. Desperately ill prostate cancer patients who have failed chemotherapy need this drug to survive longer. The manufacturer’s conditions and the PBAC’s rationalization of cost containment are severely restricting who will be eligible.

      Abiraterone also needs to be registered by the TGA and listed for PBS subsidy to prolong lives of advanced prostate cancer patients who haven’t yet received chemotherapy. As this process is very slow they also should be included (I’m told Janssen-Cilag is negotiating with the TGA).

      Cabinet could now approve a PBS subsidy as the Federal Budget has provided $691m for new listings.

      Getting the numbers on this petition could hasten the process. 4,812 interested persons have now signed this petition. I ask all who haven’t signed it to do so and everyone to circulate this request to their contacts. See http://chn.ge/QsuSHc The issues are discussed HERE: www.prostate-cancer-medication.blogspot.com/

    6. Reached 4,000 signatures
    7. Prostate Cancer: Not much hope yet for new drug but …

      Tony Musgrave
      Petition Organizer

      01May13: There is not much hope yet for Australian men with incurable prostate cancer who need Abiraterone unless they are rich and chemotherapy is not working

      The approval process for the new drug, also called Zytiga, appears to have stalled. There is no positive news, just one small ray of hope for the future.

      I am reliably informed that the manufacturer, Janssen-Cilag is currently working with the TGA to have Abiraterone registered for the treatment of mCRPC patients who have not received chemotherapy (as is now the case in the USA) and intends to seek PBS subsidy for this indication. Unfortunately, this process can seem interminable.

      This has to succed to save Australian patients from a premature painful death.

      Please ask anyone who has not yet signed this petition to the Minister for Health, Tanya Plibersek, to do so. Read more below and see my blog at: http://prostate-cancer-medication.blogspot.com.au/ .

    8. Government Inaction on New Prostate Cancer Drug Gets Media Attention

      Tony Musgrave
      Petition Organizer

      In “The International News Magazine” on Thursday, 28 March 2013 Greg Rogers published and article, “Prostate Cancer Treatment Zytiga Needs Listing on the Pharmaceutical Benefits Scheme” (URL for article: http://goo.gl/saNM9 ).

      Greg also provided the following link to a letter from The PCFA (Prostate Cancer Foundation of Australia) to the Minister urging immediate action. Read that letter here.

      This issue was also explored by Rachael Brown on 31 March 2013 in an article in the Sydney Morning Herald, "Prostate cancer drug tied up in red tape" (See: http://goo.gl/hEgFl ).

      You have already helped change the discrimination against many incurable prostate cancer patients in Australia by signing the petition

      You have already helped change the discrimination against many incurable prostate cancer patients in Australia by signing this petition. You can continue to help by again broadcasting this request to your contacts asking them to sign this petition. All such help is much appreciated

    9. Government Inaction on New Prostate Cancer Drug Gets Media Attention

      Tony Musgrave
      Petition Organizer

      16 April, 2013

      In “The International News Magazine” on Thursday, 28 March 2013 Greg Rogers published and article, “Prostate Cancer Treatment Zytiga Needs Listing on the Pharmaceutical Benefits Scheme” (URL for article: http://goo.gl/saNM9 ).

      Greg also provided the following link to a letter from The PCFA (Prostate Cancer Foundation of Australia) to the Minister urging immediate action. Read that letter here.

      This issue was also explored by Rachael Brown on 31 March 2013 in an article in the Sydney Morning Herald, "Prostate cancer drug tied up in red tape" (See: http://goo.gl/hEgFl ).

      You have already helped change the discrimination against many incurable prostate cancer patients in Australia by signing this petition. You can continue to help by again broadcasting this request to your contacts asking them to sign this petition. All such help is much appreciated. Read more of this update at my BLOG: http://prostate-cancer-medication.blogspot.com.au/ .

      Here is a bit of further

    10. Reached 750 signatures
    11. Endless reviews fail to get abiraterone to prostate cancer sufferers

      Tony Musgrave
      Petition Organizer

      Thanks again to all those who have already signed my petition http://chn.ge/QsuSHc
      Could you please circulate this link to as many others as possible to sign it so that the petition can gain influence with the Minister for Health. In November, for the fourth time in 12 months, the PBA Committee is again reviewing whether to subsidize the new prostate cancer drug abiraterone for patients have failed chemotherapy. These patients need it. So do those who have not had chemo. Abiraterone can extend all their lives. It has a good safety record but due process as well as cost is delaying its listing. In the absence of quick action lots of men are going to die sooner from painful prostate cancer re-growths because of tardiness and the government’s “cost-minimization” policy.
      Anyone who wants to help can sign at: http://chn.ge/QsuSHc

    12. Reached 250 signatures

    Supporters

    Reasons for signing

    • Christine Shaw DURACK, AUSTRALIA
      • 6 days ago

      A friend has prostate cancer

      REPORT THIS COMMENT:
    • Lilian Camenzuli AUSTRALIA
      • 9 days ago

      My husband is being treated for metastatic prostate cancer and if the Androgen deprivation Therapy does not work, it is unfair that he should have to endure chemotherapy before being given access to this drug.

      REPORT THIS COMMENT:
    • Tracey Oliver AUSTRALIA
      • 16 days ago

      I can't understand why this wouldn't be important to anyone with empathy for their fellow human being.

      REPORT THIS COMMENT:
    • Annie Simpson COOLUM BEACH, AUSTRALIA
      • 17 days ago

      One of my closest friends is living with advanced prostate cancer. I'm 100% behind this campaign

      REPORT THIS COMMENT:
    • Maurice Gourley BUDERIM, AUSTRALIA
      • 17 days ago

      Brothers and Sisters there is a massive injustice happening for men with advanced prostate cancer in Australia. This injustice condemns those of us with advanced prostate cancer to endure a gauntlet of ineffective Chemotherapy before we are entitled to have access to a far superior and more side effect free alternative which is readily available in the drug Abiraterone . Even if we survive the Docetaxal chemotherapy our immune function may be so badly compromised by it that we might not benefit from the Abiraterone at that stage. There is clear evidence that the Abiraterone is far superior to the Docetaxel chemotherapy for Hormone resistant prostate cancer. The Government is refusing to place Abiraterone on the PBS ahead of Docetaxel for purely financial reasons. Please help us to continue to address this injustice by signing this partition to demand that the drug be made available to all patients without having to endure the ineffective chemotherapy first. The Abiraterone has been approved elsewhere in the world for treatment prior to Docetaxal chemotherapy because research has confirmed it to be far superior.

      REPORT THIS COMMENT:

    Develop your own tools to win.

    Use the Change.org API to develop your own organizing tools. Find out how to get started.